ConductScience.org, home
NCI-H358
API referenceFor AI assistants

Cell line · CVCL_1559

Papers138

2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.

1 to 20 of 138

Download this page as JSON
PaperJournalYearHow we knowRetractedSource
Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides.Int J Mol Sci2026Its Methods give the RRID and name the linePubMed
PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer.Cell Rep Med2026Its Methods give the RRID and name the linePubMed
Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases.Cancer Res Commun2026Its Methods give the RRID and name the linePubMed
High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay.Acta Pharm Sin B2026Its Methods give the RRID and name the linePubMed
Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer.Oncogene2026Its Methods give the RRID and name the linePubMed
Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2.J Med Chem2026Its Methods give the RRID and name the linePubMed
HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma.J Exp Clin Cancer Res2026Its Methods give the RRID and name the linePubMed
Exosomal LINC00323 accelerates angiogenesis through activating the MAPK and JAK-STAT pathways by stabilizing CDC5L in NSCLC.Cell Oncol (Dordr)2026Its Methods give the RRID and name the linePubMed
Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer.Cancer Res2026Its Methods give the RRID and name the linePubMed
Targeting KRAS Codon 13 Mutations Using Direct Combination Approaches in Non-Small Cell Lung Cancer.Cancer Discov2026Its Methods give the RRID and name the linePubMed
Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer.Mol Cancer Ther2026Its Methods give the RRID and name the linePubMed
Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer.bioRxiv2026Its Methods give the RRID and name the linePubMed
Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B.NPJ Precis Oncol2026Its Methods give the RRID and name the linePubMed
Activation of GABBR1 by New Ligand Valerate Transcriptionally Regulates ATF4-NRF2-CXCL13 Axis Mediating CD8+ T Cell Anti-Tumor Immunity.Int J Biol Sci2026Its Methods give the RRID and name the linePubMed
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.bioRxiv2026Its Methods give the RRID and name the linePubMed
Tumor-Derived Complement C3 Overexpression in STK11-Mutant Lung Adenocarcinoma Drives Tumor Growth and Immune Checkpoint Inhibitor Resistance.Cancer Immunol Res2026Its Methods give the RRID and name the linePubMed
Identification and characterization of BRAF⇔TP53 interactions in melanoma.Cell Rep2026Its Methods give the RRID and name the linePubMed
E2A selectively regulates TGF-β-induced apoptosis in KRAS-mutant non-small cell lung cancer.Mol Oncol2026Its Methods give the RRID and name the linePubMed
Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.Cancer Res Commun2026Its Methods give the RRID and name the linePubMed
A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells.Cancer Res2026Its Methods give the RRID and name the linePubMed

cell-lines-2026-11-14-0.1.0

Next page

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_1559/papers

API referenceFor AI assistants